Immune to Cancer: The CRI Blog
-
CICON18 Day 4 Update: The Role of Bacteria; Technologies to Advance Cancer Immunotherapy
The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the…
-
CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…
-
Dr. James P. Allison, CRI Scientific Director, Awarded 2018 Nobel Prize along with Dr. Tasuku Honjo
Dr. Allison’s discoveries and determination led to the development of the first FDA-approved checkpoint immunotherapy
-
Cemiplimab Becomes First Treatment Approved for Advanced Cutaneous Squamous Cell Carcinoma
Immunotherapy is now approved for patients with advanced forms of the second most common form of skin…
-
CICON18 Preview: Translating Science into Survival
Highlights from the upcoming International Cancer Immunotherapy Conference (CICON18), including regulating T cell response, tackling the tumor…
-
Recapping the Third Annual Rational Combinations 360°
In September, experts across the immunology and immunotherapy spectrum convened in Philadelphia to discuss the latest advances…
-
CRI-Funded Study Highlights the Importance of Natural Killer Cells in Immunotherapy
CRI scientists Dr. Michele Ardolino and Dr. David Raulet showed that Natural Killer cells can help eliminate…
-
Previewing the 2018 Rational Combinations 360 Conference
The third installment of the Rational Combinations 360 conference, which will be held in Philadelphia September 13-14,…
-
First Immunotherapy Approved for Patients with Small Cell Lung Cancer
Nivolumab (Opdivo®) is now available for patients with metastatic and treatment-resistant small cell lung cancer
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.